5824 related articles for article (PubMed ID: 3139843)
1. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
Croghan MK; Booth A; Meyskens FL
J Biol Response Mod; 1988 Aug; 7(4):409-15. PubMed ID: 3139843
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.
Miller RL; Steis RG; Clark JW; Smith JW; Crum E; McKnight JE; Hawkins MJ; Jones MJ; Longo DL; Urba WJ
Cancer Res; 1989 Apr; 49(7):1871-6. PubMed ID: 2647294
[TBL] [Abstract][Full Text] [Related]
5. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
6. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
7. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
[TBL] [Abstract][Full Text] [Related]
8. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
Schiller JH; Pugh M; Kirkwood JM; Karp D; Larson M; Borden E
Clin Cancer Res; 1996 Jan; 2(1):29-36. PubMed ID: 9816086
[TBL] [Abstract][Full Text] [Related]
9. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
11. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
13. Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice.
Heston WD; Fleischmann J; Tackett RE; Ratliff TL
Cancer Res; 1984 Aug; 44(8):3220-5. PubMed ID: 6430546
[TBL] [Abstract][Full Text] [Related]
14. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J
Eur J Cancer Clin Oncol; 1986 Jun; 22(6):685-9. PubMed ID: 3091371
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2.
Robinson WA; Mughal TI; Thomas MR; Johnson M; Spiegel RJ
Immunobiology; 1986 Sep; 172(3-5):275-82. PubMed ID: 3804370
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
Meyskens FL; Kingsley EM; Glattke T; Loescher L; Booth A
Invest New Drugs; 1986; 4(3):257-62. PubMed ID: 3102397
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy.
Ganju V; Edmonson JH; Buckner JC
Invest New Drugs; 1994; 12(1):25-7. PubMed ID: 7960601
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon.
Edmonson JH; Kovach JS; Buckner JC; Kvols LK; Hahn RG
Cancer Res; 1988 Nov; 48(22):6584-6. PubMed ID: 3141046
[TBL] [Abstract][Full Text] [Related]
19. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in skin malignant tumors].
Gan To Kagaku Ryoho; 1985 Apr; 12(4):936-42. PubMed ID: 2985007
[TBL] [Abstract][Full Text] [Related]
20. Dose-related alpha-difluoromethylornithine ototoxicity.
Croghan MK; Aickin MG; Meyskens FL
Am J Clin Oncol; 1991 Aug; 14(4):331-5. PubMed ID: 1862765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
